Close Menu

Caris

The company plans two new versions of its MyPRS test later this year, including a pharmacogenomic enhancement called MyPRS RX and a version called MyPRS Plus that will perform myeloma subgroup analysis.

Startup Signal Genetics has decided to partner with specialty labs that have existing relationships with its target market instead of creating its own sales organization.

Movers & Shakers

Premium

Richard Bender

New Releases

Premium

Caris Target Now for Ovarian Cancer

Pairings

Premium

Sheila Walcoff, Amy Jensen Cunniffe, Gary Palmer

Movers & Shakers

Premium

Amy Jensen Cunniffe, Leonhard Pollack, Mark Pittman

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

Pairings

Premium

Bernd Brust, Nicolas Barthelemy, Andy Tasinato, Elodie Ristorcelli, Gherici Hassaine, Dan Holterman, Wang-Juh Chen, Jorge Schettini, Tassilo Hornung

Pages

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.